AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Fennec Pharmaceuticals Inc.
Video analysis: FENC
All videosNo video analysis for this stock yet. Request one from our team.
News: FENC
Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Adherex Technologies Q2 Earnings Call Highlights
Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2026 financial results before the opening of the U.S. financial markets on Tuesday, August 11, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
Adherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
Investors need to pay close attention to FENC stock based on the movements in the options market lately.
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 22, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Similar companies
-
Eupraxia Pharmaceuticals Inc.
EPRX
·
NASDAQ
Compare
-
Aardvark Therapeutics, Inc. Common Stock
AARD
·
NASDAQ
Compare
-
Cartesian Therapeutics, Inc.
RNAC
·
NASDAQ
Compare
-
Prelude Therapeutics Incorporated
PRLD
·
NASDAQ
Compare
-
Caribou Biosciences, Inc.
CRBU
·
NASDAQ
Compare
-
Avalo Therapeutics, Inc.
AVTX
·
NASDAQ
Compare